secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xilio Therapeutics, Inc. (XLO)
CIK:        0001840233
Form:       8-K
Filed at:   2022-01-06T23:59:59+00:00
Accession:  0001558370-22-000083
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Xilio Therapeutics Appoints Yuan Xu, Ph.D., to Board of Directors
-----------------------------------------------------------------

- Board expanded from 8 to 9 directors; Dr. Xu appointed as Class II director effective Jan 4, 2022.
- Dr. Xu is former CEO of Legend Biotech and held senior roles at Merck, Gilead, Novartis.
- Her appointment comes as Xilio expects initial data readouts for XTX101 and XTX202 in 2022.
- Dr. Xu will receive standard non-employee director compensation and enter indemnification agreement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1840233/000155837022000083/0001558370-22-000083-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1840233/000155837022000083/xlo-20220104x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-22-000083

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer